Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome (NCT05786235) | Clinical Trial Compass
RecruitingNot Applicable
Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome
Italy60 participantsStarted 2022-12-06
Plain-language summary
The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS.
To construct reference intervals of placental angiogenesis markers specific to women affected by primary APS in pregnancy by measuring the levels of sFlt-1and PlGF in serum maternal serum and their sFlt-1/PlGF ratio during the trimesters of gestation (I TM, II TM and III TM).
For this aim the study will involve recruiting two groups of subjects, one will be cases and one will be controls.
Who can participate
Age range18 Years – 45 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Pregnant patients between the ages of 18 and 45 years.
✓. Diagnosis of primary APS, according to international classification criteria.
✓. Pregnant patients between the ages of 18 and 45 years.
✓. Patients with at least one previous full-term pregnancy.
✓. No diagnosis of APS, according to international classification criteria.
Exclusion criteria
✕. PMA pregnancies.
✕. Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology
✕. Previous thrombotic event
✕. Chronic renal failure not related to AD
✕. Previous history of oncology
✕. Pregnancy by PMA.
What they're measuring
1
To construct reference ranges of placental angiogenesis markers specific to women with primary APS in pregnancy